ReviewPharmacological research2020
H
Review in Pharmacological research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 46 citations in OpenAlex.
- Unlocking the gasotransmitter: hydrogen sulfide as a multitarget regulator in ischemia-reperfusion injury.Medical gas research · 2026Review
- Systemic corticosteroids for severe community-acquired pneumonia: a narrative review of mechanisms and critical appraisal of recent trials in ICU.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- S-sulfhydration: Novel insights into the antioxidant and antiinflammation in age-related diseases.Journal of advanced research · 2026Review
- Nephroprotective activity of Eysenhardtia polystachya through antioxidant, HNaunyn-Schmiedeberg's archives of pharmacology · 2025Article
- The functions of hydrogen sulfide on the urogenital system of both males and females: from inception to the present.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Engineered nanodrug targeting oxidative stress for treatment of acute kidney injury.Exploration (Beijing, China) · 2023Review
- Clinical Applications for Gasotransmitters in the Cardiovascular System: Are We There Yet?International journal of molecular sciences · 2023Review
- Attenuation of Sepsis-Induced Acute Kidney Injury by Exogenous HMolecules (Basel, Switzerland) · 2023Article
- Renal-Protective Roles of Lipoic Acid in Kidney Disease.Nutrients · 2023Review
- The Role of Gasotransmitter-Dependent Signaling Mechanisms in Apoptotic Cell Death in Cardiovascular, Rheumatic, Kidney, and Neurodegenerative Diseases and Mental Disorders.International journal of molecular sciences · 2023Review
- A FRET-Based Ratiometric HResearch (Washington, D.C.) · 2023Article
- A novel fluorescent probe for real-time imaging of thionitrous acid under inflammatory and oxidative conditions.Redox biology · 2022Article
- Recent advances on endogenous gasotransmitters in inflammatory dermatological disorders.Journal of advanced research · 2022Review
- Early Effects of Extracellular Vesicles Secreted by Adipose Tissue Mesenchymal Cells in Renal Ischemia Followed by Reperfusion: Mechanisms Rely on a Decrease in Mitochondrial Anion Superoxide Production.International journal of molecular sciences · 2022Article
- The Pathophysiology of HBiomolecules · 2022Review
- Recent development of hydrogen sulfide-releasing biomaterials as novel therapies: a narrative review.Biomaterials translational · 2022Review
- HBiomolecules · 2021Review
- Hydrogen sulfide in ageing, longevity and disease.The Biochemical journal · 2021Review
- Carbon Monoxide and Nitric Oxide as Examples of the Youngest Class of Transmitters.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI) is a syndrome affecting most patients hospitalized due to kidney disease; it accounts for 15 % of patients hospitalized in intensive care units worldwide. AKI is mainly caused by ischemia and reperfusion (IR) injury, which temporarily obstructs the blood flow, increases inflammation processes and induces oxidative stress. AKI treatments available nowadays present notable disadvantages, mostly for patients with other comorbidities. Thus, it is important to investigate different approaches to help minimizing side effects such as the ones observed in patients subjected to the aforementioned treatments. Therefore, the aim of the current review is to highlight the potential of two endogenous gasotransmitters - hydrogen sulfide (H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.